Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease

Cilomilast (Ariflo™ , SB-207499) is an orally-active, second generation phosphodiesterase (PDE) inhibitor that may be effective in the treatment of asthma and chronic obstructive pulmonary disease (COPD). It has high selectivity for the cyclic AMP-specific, or PDE4, isoenzyme that predominates in pro-inflammatory and immune cells and is ten-fold more selective for PDE4D than for PDE4A, B and C. In vitro, cilomilast suppresses the activity of many pro-inflammatory and immune cells that have been implicated in the pathogenesis of asthma and COPD and is highly active in animal models of these diseases. Cilomilast demonstrates a markedly improved side effect profile over the archetypal PDE4 inhibitor, rolipram, which has been attributed to its inability to discriminate between the high affinity rolipram binding site and the catalytic domain of the enzyme, and the fact that it is negatively charged which at physiological pH should limit its penetration in to the CNS. In humans cilomilast is rapidly absorbed after oral administration, providing dose-proportional systemic exposure up to 4 mg, completely bioavailable, has a half-life of ~ 7 h and is subject to negligible first pass hepatic metabolism. Cilomilast is extensively metabolised with decyclopentylation, acyl glucuronidation and 3-hydroxylation of the cyclopentyl ring representing the principal routes. Most of the drug is excreted in the urine (~ 90%) and faeces (6 - 7%) with unchanged cilomilast accounting for less than 1% of the administered dose. Cilomilast has been evaluated in Phase I, Phase II and Phase III trials and dose-response experiments have demonstrated a clinically significant increase in lung function and a perceived improvement in quality of life in patients with COPD. Trials of cilomilast in asthma have been less impressive although a trend towards improved lung function has been reported. Cilomilast is safe and well-tolerated at doses up to 15 mg in both short- and long-term dosing trials with a low incidence of adverse effects. No evidence for drug-drug interactions with commonly prescribed medications for COPD and asthma such as digoxin, corticosteroids, salbutamol, theophylline or warfarin has been found. Moreover, the pharmacokinetics of cilomilast are essentially the same in smokers and non-smokers, indicating that no dose adjustments of cilomilast will be required in patients with COPD. Thus, cilomilast displays a promising clinical profile in the treatment of inflammatory airway diseases, in particular COPD and the results of further Phase III trials are awaited with interest.

[1]  S. Christensen,et al.  1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma. , 1998, Journal of medicinal chemistry.

[2]  P. Norman.  PDE4 inhibitors: sustained patenting activity as leading drugs near the market , 2000 .

[3]  T. Torphy.  Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. , 1998, American journal of respiratory and critical care medicine.

[4]  P. Jeffery,et al.  Differences and similarities between chronic obstructive pulmonary disease and asthma , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[5]  C. Houghton,et al.  Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin‐2 release from murine splenocytes by interacting with a ‘low‐affinity’ phosphodiesterase 4 conformer , 1997, British journal of pharmacology.

[6]  S. Christensen,et al.  The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity. , 1995, The Journal of pharmacology and experimental therapeutics.

[7]  Jerome J. Schentag,et al.  Enhanced biotransformation of theophylline in marihuana and tobacco smokers , 1978, Clinical pharmacology and therapeutics.

[8]  D. Rogers,et al.  Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease , 2000, Expert opinion on pharmacotherapy.

[9]  S. Christensen,et al.  Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. , 1995, The Journal of pharmacology and experimental therapeutics.

[10]  D. Malone,et al.  A national estimate of the economic costs of asthma. , 1997, American journal of respiratory and critical care medicine.

[11]  C. McHorney,et al.  The MOS 36‐Item Short‐Form Health Survey (SF‐36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs , 1993, Medical care.

[12]  J. Souness,et al.  Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. , 1997, Cellular signalling.

[13]  M. Yacoub,et al.  Effects of Prostaglandin E2 and cAMP Elevating Drugs on GM-CSF Release by Cultured Human Airway Smooth Muscle Cells , 2001 .

[14]  S. Jin,et al.  Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Billah,et al.  Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. , 1999, Molecular pharmacology.

[16]  S. Rennard,et al.  PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. , 2002, American journal of respiratory cell and molecular biology.

[17]  U. Fuhr,et al.  Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. , 1992, Biochemical pharmacology.

[18]  L B Sheiner,et al.  Theophylline disposition in acutely ill hospitalized patients. The effect of smoking, heart failure, severe airway obstruction, and pneumonia. , 1978, The American review of respiratory disease.

[19]  A. Marfat,et al.  Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. , 1996, Journal of medicinal chemistry.

[20]  P. Norman.  PDE4 inhibitors 1999 , 1999 .

[21]  Alan D. Lopez,et al.  Mortality by cause for eight regions of the world: Global Burden of Disease Study , 1997, The Lancet.

[22]  M. Sears.  Descriptive epidemiology of asthma , 1997, The Lancet.

[23]  D. Grant,et al.  Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. , 1987, Drug metabolism and disposition: the biological fate of chemicals.

[24]  S. Christensen,et al.  1,4‐Cyclohexanecarboxylates: Potent and Selective Inhibitors of Phosphodiesterase 4 for the Treatment of Asthma. , 1998 .

[25]  S. Christensen,et al.  SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. , 1998, The Journal of pharmacology and experimental therapeutics.

[26]  R. Hayes,et al.  Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. , 1992, Pharmacogenetics.

[27]  D. Back,et al.  Theophylline metabolism in human liver microsomes: inhibition studies. , 1996, The Journal of pharmacology and experimental therapeutics.

[28]  A. Ammit,et al.  Tumor Necrosis Factor-a – Induced Secretion of RANTES and Interleukin-6 from Human Airway Smooth-Muscle Cells Modulation by Cyclic Adenosine Monophosphate , 2000 .

[29]  W. Jusko,et al.  Influence of cigarette smoking on drug metabolism in man. , 1979, Drug metabolism reviews.

[30]  J. Karlsson,et al.  Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a ‘low‐affinity’ phosphodiesterase 4 conformer , 1996, British journal of pharmacology.

[31]  A. Freiburghaus,et al.  Metabolism of theophylline by cDNA-expressed human cytochromes P-450. , 1995, British journal of clinical pharmacology.

[32]  L. Sansom,et al.  The influence of cigarette smoking and sex on theophylline disposition. , 2015, The American review of respiratory disease.

[33]  D. Mannino,et al.  Surveillance for asthma--United States, 1960-1995. , 1998, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[34]  M. Zanetti,et al.  Cyclic AMP-dependent regulation of lipid mediators in white cells. A unifying concept for explaining the efficacy of theophylline in asthma. , 1987, The American review of respiratory disease.

[35]  S. Christensen,et al.  Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig. , 1998, The Journal of pharmacology and experimental therapeutics.

[36]  T. Shimada,et al.  Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002. , 1989, Cancer research.

[37]  W. Jusko,et al.  Effect of smoking on theophylline disposition , 1976, Clinical pharmacology and therapeutics.

[38]  P. Norman.  PDE4 inhibitors 1998 , 1998 .

[39]  J. Jones,et al.  Life in the 21st century - a vision for all. , 1998, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[40]  P. Guzelian,et al.  Characterization of human liver cytochromes P-450 involved in theophylline metabolism. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[41]  S. Christensen,et al.  SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. , 1998, The Journal of pharmacology and experimental therapeutics.

[42]  M. M. Teixeira,et al.  Effect of PDE4 inhibitors on zymosan‐induced IL‐8 release from human neutrophils: synergism with prostanoids and salbutamol , 1998, British journal of pharmacology.

[43]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[44]  Alan D. Lopez,et al.  Evidence-Based Health Policy--Lessons from the Global Burden of Disease Study , 1996, Science.

[45]  A. Govindarajan,et al.  Conformational difference between PDE4 apoenzyme and holoenzyme. , 2000, Biochemistry.

[46]  S. Christensen,et al.  Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding. , 1996, Biochemical pharmacology.

[47]  S. Loft,et al.  Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. , 1992, Carcinogenesis.

[48]  S. Ramsey,et al.  The economic burden of COPD. , 2000, Chest.

[49]  C. Wermuth,et al.  Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. , 1989, Journal of medicinal chemistry.

[50]  Phillips Yy,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.

[51]  M. Houslay,et al.  The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. , 1998, Advances in pharmacology.

[52]  S. Spielberg,et al.  A urinary metabolite ratio that reflects systemic caffeine clearance , 1987, Clinical pharmacology and therapeutics.

[53]  R. Owens,et al.  PDE 4 inhibitors: the use of molecular cloning in the design and development of novel drugs , 1997 .

[54]  S. Christensen,et al.  Suppression of human inflammatory cell function by subtype‐selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B , 1999, British journal of pharmacology.

[55]  Thomas Sutton.  On Pulmonary Diseases , 1816, The London medical and physical journal.

[56]  A. Hatzelmann,et al.  Anti-Inflammatory and Immunomodulatory Potential of the Novel PDE 4 Inhibitor Roflumilast in Vitro , 2001 .

[57]  M. Teixeira,et al.  Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? , 1997, Trends in pharmacological sciences.

[58]  S. Christensen,et al.  Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. , 1999, Pulmonary pharmacology & therapeutics.

[59]  J. Barsig,et al.  In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. , 2001, The Journal of pharmacology and experimental therapeutics.

[60]  S. Hurd,et al.  The impact of COPD on lung health worldwide: epidemiology and incidence. , 2000, Chest.

[61]  J. Fozard,et al.  Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. , 1996, TIPS - Trends in Pharmacological Sciences.